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The importance of the genetic factor in the aetiology of premature ovarian failure (POF) is emphasized by the high
percentage of familial cases and X chromosome abnormalities account for 10% of chromosomal aberrations. In this
study, we report the detailed analysis of 4 chromosomal abnormalities involving the X chromosome and associated
with POF that were detected during a screening of 269 affected women. Conventional and molecular cytogenetics
were valuable tools for locating the breakpoint regions and thus the following karyotypes were defined: 46,X,der(X)t
(X;19)(p21.1;q13.42)mat, 46,X,t(X;2)(q21.33;q14.3)dn, 46,X,der(X)t(X;Y)(q26.2;q11.223)mat and 46,X,t(X;13)(q13.3;q31)dn.
A bioinformatic analysis of the breakpoint regions identified putative candidate genes for ovarian failure near the
breakpoint regions on the X chromosome or on autosomes that were involved in the translocation event. HS6ST1,
HS6ST2 and MATER genes were identified and their functions and a literature review revealed an interesting
connection to the POF phenotype. Moreover, the 19q13.32 locus is associated with the age of onset of the natural
menopause. These results support the position effect of the breakpoint on flanking genes, and cytogenetic
techniques, in combination with bioinformatic analysis, may help to improve what is known about this puzzling
disorder and its diagnostic potential.
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Female infertility is an important health and social dis-
order and one of its causes is premature ovarian failure
(POF, OMIM 311360) which is becoming an increasingly
appealing research subject due to its high incidence rate
and the absence of an effective treatment [1]. POF is
defined as an early ovarian dysfunction characterized by
amenorrhea and elevated gonadotropin serum levels be-
fore the age of 40 [2]. The median age of natural meno-
pause is around 50, but 9.7% of women experience
menopause before 45 (early menopause) and 1.9% under
40 years of age [3].
The pathogenetic mechanisms leading to POF are
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portion of POF cases still remain idiopathic [4-6].
Chromosomal defects are frequently associated with
POF, especially aberrations involving the X chromosome
that account for 5-10% of cases [1,7,8], including numer-
ical and structural abnormalities such as deletions, inver-
sion and X;autosome translocations [9,10]. The
cytogenetic and molecular investigations of these abnor-
malities allowed the identification of two critical regions
on the long arm of the X chromosome, at Xq13-q21 and
Xq26-27 [11-14]. Candidate genes were identified in the
breakpoint regions of the X chromosome, but the actual
genetic determinants still remain unknown because
these hypothetical candidates need to be confirmed by
further investigations [15]. However, the mechanisms
that underlie POF’s aetiology might be due to factors
other than gene interruption. Indeed, the disruption of
critical gene-poor regions might influence the expression
of flanking genes [16], or X chromosome translocationstral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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follicle maturation due to mispairing [14,17].
In this study, we performed a detailed cytogenetic ana-
lysis of 4 chromosomal abnormalities involving the X
chromosome and associated with POF that were detected
during a screening of 269 affected women [8,18,19]. We
identified two de novo balanced translocations and two
unbalanced, maternally inherited, translocations. Mo-
lecular cytogenetic techniques in combination with bio-
informatic analysis made it possible to define the
breakpoint region of each cytogenetic abnormality and to
search for candidate genes involved in the pathogenesis
of POF.
Results
Banding cytogenetics
Banding cytogenetic techniques, such as QFQ (Q-bands by
Fluorescence using Quinacrin), GTG (Giemsa-Trypsin-
Giemsa) and RHG (R-bands by heating using Giemsa)
banding, showed the presence of abnormal karyotypes in 4
patients and allowed the chromosomal aberrations to be
approximately defined (Figure 1A). Chromosome analysis
revealed 46,X,der(X)t(X;19)(p21;q13) in case 1;, 46,X,t(X;2)
(q21;q14) in case 2; 46,X,der(X)t(X;Y)(q25-26;q11.22) in
case 3 and 46,X,t(X;13)(q13.3;q31) in case 4. In case 3 the
q arm telomeric region of the derivative chromosome was
identified as DA/DAPI (Distamicin A/4',6-diamidino-2-
phenylindole) positive (data not shown). Cases 1 and 3
showed maternal inherited chromosomal aberrations. In
particular, the mother of case 1 had an X;19 balanced
translocation and the sister’s karyotype was the same as
the proband. Both were able to conceive, the mother
experienced menopause at 39 years of age and the sister
had a normal ovarian cycle at the time of diagnosis
(Figure 1C). The karyotype of the mother of case 3
revealed the same karyotype as her daughter and she
experienced menopause at 40 years of age, a borderline
case between POF and early menopause (Figure 1D).
The X inactivation pattern was analysed by means of
RBA (Reverse-bands with acridine orange staining) band-
ing for cases 1 and 3 as, in these cases, a derivative
chromosome was identified (Figure 1B). In case 1 the de-
rivative X chromosome was late replicating, and so was
inactivated, but der(X) resulted completely inactivated in
73% of metaphases, while 27% showed an incomplete
and discontinuous inactivation of autosomal material.
Case 3 showed a complete late replication of the deriva-
tive X chromosome in 100% of the metaphases.
Molecular cytogenetics and breakpoint mapping
As each chromosomal abnormality is unique, the meth-
odologies used were selected based on case-specific
requirements. In order to further characterize the
chromosomal abnormalities several FISH (Fluorescencein situ hybridization) experiments were assessed by
means of different probes corresponding to specific telo-
meric sequences and partial or whole chromosome li-
braries (Figure 2). Several FISH experiments using a
panel of BAC (bacterial artificial chromosome) and PAC
(P1 derived artificial chromosome) probes were carried
out in order to determine the exact localization of each
chromosomal breakpoint. All the probes used to identify
the breakpoints and the results of each hybridization sig-
nal are listed in Additional file 1: Table S1. In case 1 the
FISH analysis using a wcp19 (whole chromosome paint-
ing) probe revealed a derivative chromosome with
chromosome 19 material at the telomere of the deriva-
tive chromosome q arm (Figure 2A). The breakpoint on
chromosome X was localized at Xp21.1 between the
RP13-172P16 and RP11-87M18 probes (Figure 2B). Fur-
thermore, the breakpoint on chromosome 19 was
mapped at 19q13.42, between RP11-174J9 and CTD-
2594I19. A dual colour FISH of case 2, using wcpX and
wcp2 probes, confirmed the banding cytogenetic results
and revealed an apparently balanced translocation be-
tween the long arm of chromosome X and chromosome
2 (Figure 2C). The case 2 breakpoint on the X chromo-
some was located at Xq21.33 as the RP11-390F10 probe
showed the presence of hybridization signals on both
the derivative chromosomes (Figure 2D). The RP11-
150O15 probe defined the breakpoint on chromosome
2q14.3 for the same reason. In case 3 the DXZ1 and
DYZ1 probes allowed the identification of a derivative X
chromosome with the presence of Y heterochromatic
regions at the telomere of the q arm (Figure 2E). The
breakpoint on chromosome X of case 3 was identified
by means of a single nucleotide polymorphism (SNP)
array analysis (Figure 2F). The association of a loss of
heterozygosity (LOH) and a copy number change score
of 0.8-1.7 allowed the identification of the breakpoint at
Xq26.2, specifically between rs5977559 and rs202735.
No other alterations in copy number changes were
found in the genome-wide analysis. In order to map the
breakpoint on the Y chromosome, we analysed the amp-
lification of microsatellite polymorphic markers included
in the Y Chromosome Azoospermia Factor (AZF) Ana-
lysis System (Promega, Madison, WI, USA) [Additional
file 2]. This analysis allowed the breakpoint to be
mapped specifically at Yq11.223, between DY5379 and
DYF51S1 markers. Case 4 karyotype was characterized
by a translocation that occurred between chromosome X
and chromosome 13: this hypothesis was confirmed by a
FISH analysis using wcpX and 13qtel probes (Figure 2G
and 2H). An array comparative genomic hybridization
(aCGH) analysis was performed to check whether the
translocation was balanced and to reveal any additional
alterations. Unfortunately for us, the aCGH data were not in-
formative enough for the breakpoint to be determined as the
Figure 1 Conventional cytogenetics. Partial karyotype of cases 1–4 through QFQ, GTG or RHG banding. B. RBA banding allowed the
identification of the late replicating derivative X chromosome in cases 1 and 3 (arrows). C. Family pedigree of case 1. D. Family pedigree
of case 3.
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location between chromosome X and chromosome 13.
However, cryptic deletions and duplications due to the trans-
location event were excluded. The aCGH analysis showed 22
copy number variations (CNVs): 14 losses and 8 gains. The
CNVs ranged in size from 12Kb to 1270Kb and 16 of them
contained known genes [details in Additional file 3: Table
S3]. All the observed CNVs overlapped with previously
described CNVs: some of them are described as polymorphic
on the Database of Genomic Variants [20], others are
included in an Italian Database of Human CNVs collected in
patients with mental retardation [21] and in none of our
patients was any mental retardation noticed. The results of
each specific chromosomal aberration, the breakpoint pos-
ition and the related karyotype are summarized in Figure 3.
Bioinformatic analysis
A bioinformatic analysis was performed in order to iden-
tify possible candidate genes for the POF phenotype. The
investigation was performed 1 Mb upstream and down-
stream from each specific breakpoint, consulting theUCSC Genome Browser [22] and NCBI database [23].
Candidate genes were selected depending on their func-
tion, tissue expression and related scientific literature. In
case 1 only an open reading frame (cXorf30) and a
pseudogene (RPS15AP40) were found in the breakpoint
region on chromosome X and no proper genes were
detected in the flanking regions. On chromosome 19 the
breakpoint fell in 19q13.42. This region, in or near the
BRSK gene (+9.8 Kb), has been mapped as being possibly
associated with the age at natural menopause [24-26].
Moreover, another interesting gene, MATER (Maternal
Antigen that Embryos Require), was found in the triso-
mic region of chromosome 19 (19q13.42!19qtel).
MATER expression is restricted to the oocyte and its ac-
tivity is essential for early embryonic development
[27,28]. In case 2 the breakpoint on X chromosome fell
near the DIAPH2 gene (−680Kb). On chromosome 2 the
HS6ST1 gene was considered for this analysis. In case 3,
in the breakpoint on chromosome X, no genes were
found, but the HS6ST2 gene was localized 720Kb down-
stream. The definition of the Case 4 breakpoint did not
Figure 2 Molecular cytogenetic analysis. Case 1. A. FISH analysis by means of wcp19 showing two normal chromosomes 19 and one
derivative chromosome positive for wcp19 probe signal. B. FISH using RP11-87M18 (Xp21.1) and DXZ1 probes showing hybridization signals both
on normal and derivative X chromosomes. Case 2. C. Dual colour FISH with wcpX (red) and wcp2 (green) probes showing a X;2 translocation. D.
FISH using DXZ1 and RP11-150O15 probe, which is present on both derivative chromosomes and on the normal chromosome 2. Case 3. E. Dual
colour FISH by means of DXZ1 (green) and DYZ1 (red) that identify the heterochromatic Y region on the derivative X chromosome. F. SNP
analysis localized the breakpoint region in Xq26.2, identified as a monosomy trait from Xq26.2!Xqtel. Case 4. G. wcpX probe shows the
presence of a translocation between chromosome X and chromosome 13. H. 13qtel probe displays hybridization signals on normal chromosome
13 and on derivative X chromosome.
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that different mechanisms underlie POF aetiology.
Discussions
POF is a puzzling disorder as its aetiology is very hetero-
geneous and most cases are still idiopathic. However, the
incidence of familial cases among POF patients is esti-
mated to exceed 30% [29,30], suggesting a genetic basis
for some cases of idiopathic POF. In particular, the asso-
ciation between POF and X chromosome abnormalities
has been extensively described [4]. Chromosomal anom-
alies occur in 8.8-33% of women with POF [31] and 10-
15% of cases are X chromosome abnormalities, such as
numerical and structural aberrations (deletions, inver-
sions and X;autosome translocations) [1,7,8]. This study
characterizes the chromosomal abnormalities identified
in four patients affected by POF and included in a co-
hort of 269 patients [8,18,19]. Specifically, we identified
4 chromosomal abnormalities involving the X chromo-
some with 4 different breakpoint localizations: two de
novo balanced translocations 46,X,t(X;2)(q21.33;q14.3) in
case 2 and 46,X,t(X;13)(q13.3;q31) in case 4 and two ma-
ternal inherited unbalanced translocations, 46,X,der(X)t
(X;19)(p21.1;q13.42) in case 1 and 46,X,der(X)t(X;Y)(q26.2;q11.223) in case 3. This genetic heterogeneity
highlights both the importance of the X chromosome in
POF aetiology and the complexity of the POF disorder.
However, it is not possible to exclude the involvement of
autosomal genes in the onset of ovarian insufficiency as
some genes located on autosomes have been associated
with the POF phenotype, for example INHA, FSHR and
FOXL2 [32-34]. Theoretically, fertility impairment in
patients with chromosomal abnormalities might be
explained in various ways. First of all, chromosomal
anomalies might disrupt a gene that is important for go-
nadal function [14]; alternatively the breakpoint may fall
in gene-poor regions and, in this case, the translocation
might induce a long-range position effect in the expres-
sion of genes flanking the breakpoint, suggesting an
epigenetic control [16,35]. Moreover, structural rearran-
gements involving the X chromosome may disrupt the
normal pairing at meiosis, leading to meiotic arrest [17].
However, the pattern of chromosomal aberrations is still
not clearly comprehensible: chromosomal alterations with
breakpoints spanning on chromosome X have also been
identified in females with normal ovarian function [16,36].
In case 1 the bioinformatic analysis of genes in the
breakpoint region on chromosome X did not identify
Figure 3 Breakpoint definitions. Ideograms showing each specific chromosomal aberration found in cases 1–4 and breakpoint localization.
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ZFX gene (X-linked zinc finger protein at Xp21.2) may
be an important factor as it has been identified as a can-
didate gene for ovarian failure [36,37]. The gene content
analysis on chromosome 19 raised some interesting
points for discussion. Firstly, the breakpoint fell in
19q13.42 and this locus has been mapped as being asso-
ciated with the age of natural menopause by two inde-
pendent research groups through genome-wide
association studies using SNP analysis [24,26]. In case 1
the breakpoint fell near the BRSK1 gene that might in-
fluence the secretion of gonadotropin releasing hormone
(GnRH) affecting the menstrual cycle since it is highly
expressed in the human brain and is associated with ves-
cicle transport and release at the axonal terminals [24].
Additionally, case 1 might experience partial trisomy for
the additional material of chromosome 19 (19q13.42!19qter) on the derivative X chromosome due to in-
complete inactivation of the derivative chromosome
[38,39]. Also the MATER gene (Maternal Antigen that
Embryos Require) was mapped at 19q13.43 and it is a
maternal oocyte protein essential for early embryonic
development in mice and an autoantigen associated with
autoimmune oophoritis, a mouse model of autoimmune
POF [27]. The MATER was identified as a causative
gene in a POF patient with a psudic(1;19)(q10;q13.42) by
Northup and coworkers [40]. Moreover, the Mater gene
in mice is specifically transcribed in oocytes [28] and
human and mouse MATER genes are conserved and
share several structural similarities. Although the exact
mechanism of action of the MATER gene product is still
unknown, knockout mice show female infertility [27]
and so a change in gene dosage (in this case trisomy)
might influence fertility [40]. Considering that we have
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aberration that involves a putative role for MATER, this
gene may be a real candidate in POF aetiology and fur-
ther investigations may be helpful.
Two isoforms of HS6ST gene were identified in 2
chromosomal breakpoints in our patients: HS6ST1 gene
at 2q21 (−216Kb) in case 2 and HS6ST2 gene at Xq26.2
(+720Kb) in case 3. HS6ST1 and HS6ST2 are members
of the heparan sulfate sulfotransferase gene family that
catalyse the transfer of sulfate to heparan sulfate.
Heparan sulfate proteoglicans are ubiquitously expressed
on the cell surface and interact with various ligands in-
fluencing cell growth, differentiation, adhesion and mi-
gration [41]. In 2000 Davison and Conway identified
HS6ST as a possible candidate gene for POF aetiology by
analyzing the breakpoint on the X chromosome in a
family with POF [42]. HS6ST2 in particular is expressed
preferentially in the ovary [43] and it might influence
oocyte development by inhibiting a proper interaction
with follicular growth factors [42]. Moreover, HS6ST1
gene mutations have recently been associated with idio-
pathic hypogonadotrophic hypogonadism [44], thereby
increasing the evidence for a possible role of these two
isoforms in gonadal fertility. Taking into account that
HS6ST2 was identified as a putative gene responsible for
POF phenotype in a family by Davison and co-workers
[42], and that we identified the possible involvement of
both isoforms in two more cases, the suggestion that
this gene family may play a role in POF aetiology is rea-
sonable and should indeed be further investigated.
Additionally, in case 2 the breakpoint fell in Xq21.33,
near the DIAPH2 gene (−680Kb), a well-known gene in
POF aetiology [45]. The breakpoint was quite distant,
but it was not possible to exclude the disruption of some
regulatory element in cis, or a long-range effect, that
would influence gene expression [16].
The case 4 karyotype revealed the breakpoint as being
located at Xq13.3 in the POF2 critical region [14,16], but
no candidate genes were identified. However, the mech-
anism underlying the POF phenotype could be due to a
direct effect of the chromosomal rearrangement itself
without the involvement of specific genes, suggesting a
sort of epigenetic control of gene-poor critical regions in
patients with X chromosome aberrations [35,46].
The X chromosome inactivation (XCI) pattern is an-
other important feature in unbalanced translocations in-
volving X chromosome. In case 3 RBA banding revealed
the complete and preferential inactivation of der(X),
whereas in case 1, 73% of metaphases showed a
complete inactivation of derivative X chromosome, but
27% of metaphases evidenced an incomplete and discon-
tinuous inactivation of autosomal material, leading to a
mosaic for a partial trisomy of chromosome 19 [39]. Fur-
thermore, 15% of genes on the X chromosome escape Xinactivation [47] and so the translocation might have
caused an improper inactivation of derivative X chromo-
some and haploinsufficiency of genes involved in ovarian
function [19,38]. In case 3 the presence of Y heterochro-
matic regions may affect the inactivation of der(X)
[1,48]. Considering the breakpoint localizations, the
XIST (X inactivation-specific transcript) region (Xq13.2)
is located on the specific derivative X chromosome of
each case. Cases 2 and 4 are balanced translocations and
the patients showed no phenotypic abnormality except
for ovarian disfunction. Thus, we may assume that XCI
in these two cases was skewed, with the derivative X
chromosome typically remaining active and the normal
X chromosome being inactivated [49]. Indeed, atypical
XCI would result in monosomy of autosomal genes,
probably leading to a more severe phenotype [50,51].
Cases 1 and 3 are both maternal inherited transloca-
tions but the respective mothers experienced menopause
at a later age than the daughters. The difference in the
age of onset could have several causes. Different X in-
activation patterns may influence the age of menopause
onset [13,19,52], but also the effect of the genetic back-
ground, such as predisposing polymorphisms in the
affected individuals, plays a crucial role. In these cases,
identical aberrations might cause no apparent symptoms
in mothers but severe clinical presentations in the off-
spring [53-55]. In addition, environmental factors influ-
ence the phenotype and, consequently, also the age of
menopause onset [56].
aCGH was performed on case 4 and the data ana-
lysis revealed no major chromosomal alterations. All
the observed CNVs overlapped with described poly-
morphic CNVs. The comparison with the literature
data [49,57-59] showed 2 CNVs significantly asso-
ciated with the POF phenotype that overlapped with
2 CNVs found in the case 4 molecular karyotype:
Xq13.3 [58] and 14q32.33 [59]. However, in our pa-
tient these overlapping CNVs were smaller and did
not include genes. Moreover, 3 other CNVs described
by Aboura and co-workers overlapped with the case 4
CNVs, but these variants were described as not statis-
tically significant compared to CNVs in control popu-
lations: 1p36.13, 8p23.1 and 15q11.2 [59]. Although a
partial overlapping was found, further studies are
required to asses whether there really is an associ-
ation between these CNVs and the POF phenotype.
Conclusions
This study confirms the importance of the X chromo-
some in POF aetiology, but also highlights the complexity
of this disorder since different cytogenetic abnormalities
lead to the same phenotype. The identification of genes
probably involved in ovarian development in the regions
flanking the breakpoints supports the hypothesis that the
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ing to the POF phenotype. Detailed cytogenetic defini-
tions of new cases of POF will be instrumental in
acquiring further knowledge and in identifying all the
genetic determinants involved in the POF aetiology. The
link between cytogenetic investigation and bioinformatic
analysis may be useful for identifying those putative
genes most likely to be involved in ovarian insufficiency.
Methods
Clinical population
The cohort investigated in this study has been described
previously [8]. Inclusion criteria were the cessation of
menses for a period of 6 months or longer before or at
the age of 40 and FSH (follicle-stimulating hormone)
levels ≥ of 40 IU/l, detected on two different occasions.
All of the patients underwent a complete clinical assess-
ment in order to exclude any of the known POF related
conditions (i.e. ovarian surgery, autoimmune diseases,
Turnerian phenotype). All patients gave their informed
consent prior to their inclusion in the study. In this
study, we decided to investigate the role of the X
chromosome in POF aetiology and, specifically, we char-
acterized the localization of the breakpoint regions in
four cases of translocation involving the X chromosome.
The age of POF onset was 36 years in case 1, 20 years in
case 2, 27 years in case 3 and 22 years in case 4.
Cell lines
Epstein-Barr virus (EBV)-transformed lymphoblastoid
cell lines were provided by the Galliera Genetic Bank,
Galliera Hospital (Genoa, Italy). Lymphoblastoid cell
lines were grown in RPMI 1640 (Euroclone S.p.A.,
Milan, Italy) supplemented with 10% foetal bovine serum
(PBI International, Milan, Italy) and 2 mM L-glutamine
(Euroclone S.p.A., Milan, Italy). Metaphase chromo-
somes were prepared as previously described [18].
Banding cytogenetics
Metaphase-chromosome spreads were obtained from
phytohaemagglutinin-stimulated peripheral blood lym-
phocytes. QFQ, GTG, RHG, RBA banding and DA/DAPI
staining were performed using standard protocols. At
least 20 metaphases were analysed for each sample and a
further 50 cells were assessed to exclude sex chromo-
some mosaicism. The karyotype was expressed following
the guidelines of the International System for Chromo-
some Nomenclature 2009 (ISCN 2009) [60].
FISH analysis
Fluorescence in situ hybridization was carried out using
various commercial probes: wcpX, 13qtel (Vysis, Abbott
Molecular, Abbott Park, Illinois, U.S.A.), wcp2, wcp19,
DXZ1 and DYZ1 (ONCOR, Gaithersburg, MD, USA).Every experiment was performed according to the manu-
facturer's instructions. To define the breakpoint regions,
probes were selected by consulting the UCSC Genome
Browser [22] and NCBI [23]. Bacterial artificial chromo-
some (BAC) and P1 derived artificial chromosome (PAC)
probes were provided by the Wellcome Trust Sanger In-
stitute, UK, and by Prof. M. Rocchi, University of Bari,
Italy and are summarized in Additional file 1: Table S1.
FISH was performed as described previously [18]. Briefly,
probes were labelled by nick translation using digoxi-
genin(DIG)-11-dUTP (Roche Diagnostics, Indianapolis,
IN, USA). Probes were hybridized to metaphase chromo-
somes overnight and then washed. Detection of digoxi-
genin probes was obtained by means of 1 μg/ml anti-DIG
Rodaminate antibodies (Roche Diagnostics, Indianapolis,
IN, USA). Chromosomes were counterstained with DAPI
(4',6-diamidino-2-phenylindole). A mean number of 10
metaphases were analysed for each FISH experiment,
searching for the presence/absence of probe signals on
normal and derivative chromosomes. All the images were
taken through a Leica DM 5000B microscope (Leica
Microsystems, Wetzlar, Germany) equipped with a
Charge Coupled Device (CCD) camera and analysed by
means of Chromowin software (Tesi Imaging Srl, Vene-
zia, Italy). The breakpoint localization was determined by
FISH analysis and the searching for putative candidate
genes in or near the breakpoint region was performed
using the most recent human reference sequence (NCBI
Build 37.2).
DNA extraction
Genomic DNA was extracted from patients’ blood or
from lymphoblastoid cell-line cultures using the Wiz-
ard Genomic DNA purification Kit from Promega
according to manufacturer’s protocol and DNA con-
centration was determined by means of a NanoDrop
ND-1000 spectrophotometer (NanoDrop Technologies,
Wilmington, DE, USA).
Microsatellite analysis
The Y Chromosome AZF Analysis System (Promega,
Madison, WI, USA) was used for an initial definition of
the breakpoint region. Additional microsatellites located
on the Y chromosome were used in order to better
localize the breakpoint site [Additional file 2]. Microsat-
ellite markers selected for this study showed more than
70% of heterozygosity and they were selected by consult-
ing the UCSC Genome Browser [22].
Array CGH
A CNV analysis was performed using the Agilent
Human Genome CGH Microarray 244A kit (Agilent
Technologies, Palo Alto, CA, USA) following the manu-
facturer’s instructions. Hybridization signals were
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and DNA Analytics software (v5.0, Agilent Technologies,
Palo Alto, CA, USA). Aberration Detection Method 2
(ADM2) algorithm (threshold 5.0) was used to identify
DNA copy number aberrations. We applied a filtering
option of a minimum of 3 aberrant consecutive probes
[61] and a minimum absolute average log 2 ratio of 0.30.
UCSC human genome assembly hg18 was used as a
reference and CNVs were identified with a database inte-
grated into the Agilent Genomic Workbench analytic
software. Log 2 ratios lower than −0.30 were classified as
losses, those greater than 0.3 as gains.
SNP analysis
The SNP mapping assay was performed by Genopolis
(University of Milan-Bicocca, Milan, Italy) using an Affy-
metrix 10 K SNP mapping array (Affymetrix, Santa
Clara, CA, USA) and following the protocol recom-
mended by the manufacturer. The array was scanned
and the signal intensity was measured using GCOS
(Gene Chip Operating System). Data were analysed
using CNAG (Copy Number Analyser for GeneChip)
software version 1.0, evaluating DNA copy number and
LOH.
Additional files
Additional file 1: Table S1. List of BAC and PAC probes used in the
study and results of FISH hybridization signal.
Additional file 2: Table S2. Microsatellite markers used to identify the
breakpoint on chromosome Y.
Additional file 3: Table S3. List of CNVs detected by aCGH of case 4.
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Q-bands by Fluorescence using Quinacrin; RBA: Reverse-bands with acridine
orange staining; RHG: R-bands by heating using Giemsa; SNPs: Single
nucleotide polymorphisms; WCP: whole chromosome painting; XCI:
X chromosome inactivation; XIST: X inactivation-specific transcript.
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